Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetrelimab||JNJ63723283|JNJ 63723283|JNJ-63723283||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Cetrelimab (JNJ-63723283 ) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 over exp||lung non-small cell carcinoma||predicted - sensitive||Cetrelimab||Phase Ib/II||Actionable||In a Phase I/II trial, Cetrelimab (JNJ-63723283) treatment demonstrated safety and resulted in an overall response rate (ORR) of 18.6% (38/204), clinical benefit rate (CBR) of 31.3% (64/204), median progression-free survival (mPFS) of 2.8 mo, and median overall survival (mOS) of 17.8 mo in patients with advanced solid tumors, with an ORR of 52.6% (10/19, all partial responses) and CBR of 73.7% (14/50) in non-small cell lung cancer patients with high CD274 (PD-L1) expression (PMID: 35298698; NCT02908906).||35298698|
|CD274 positive||melanoma||predicted - sensitive||Cetrelimab||Phase Ib/II||Actionable||In a Phase I/II trial, Cetrelimab (JNJ-63723283) treatment demonstrated safety, and resulted in an overall response rate (ORR) of 18.6% (38/204), clinical benefit rate (CBR) of 31.3% (64/204), median progression-free survival (mPFS) of 2.8 mo, and median overall survival (mOS) of 17.8 mo in advanced solid tumor patients, with an ORR of 50% (4/8, 1 complete and 3 partial responses), and CBR of 75% (6/8) in CD274 (PD-L1)-positive melanoma patients (PMID: 35298698; NCT02908906).||35298698|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02908906||Phase I||Cetrelimab||A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers||Recruiting||USA | ITA | ESP | DEU||17|
|NCT04919512||Phase II||Cetrelimab + TAR-200 Cetrelimab||A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)||Recruiting||USA | ITA | FRA | ESP | DEU | BEL||4|